Beatrice Conca
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Beatrice Conca has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Noemi Salmeri
Department of Clinical Sciences and Community Health, Dipartimento di Eccellenza 2023-2027, Università degli Studi di Milano, Via Commenda 19, 20122 Milano, Italy; Gynecology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Commenda 12, 20122 Milano, Italy
4 shared publications - Veronica Bandini
Università degli Studi di Milano Academic Centre for Research on Adenomyosis and Endometriosis, Department of Clinical Sciences and Community Health Milan
4 shared publications - Edgardo Somigliana
Infertility Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
3 shared publications - Michele Vignali
Università degli Studi di Milano Academic Centre for Research on Adenomyosis and Endometriosis, Department of Clinical Sciences and Community Health Milan
3 shared publications - Paola Viganò
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
3 shared publications - Paolo Vercellini
Academic Center for Research on Adenomyosis and Endometriosis, Department of Clinical Sciences and Community Health Università degli Studi Milano Italy
3 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Oxford University Press (OUP) in Human Reproduction Open
Playing ‘devil’s advocate’* – conservative management for benign-looking adnexal masses on ultrasound: swimming against the tide
- 19 October 2026
- Published by Oxford University Press (OUP) in Human Reproduction Open
Open AccessPlaying ‘devil’s advocate’* – conservative management for benign-looking adnexal masses on ultrasound: swimming against the tide
- Open Access
- 21 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (6) , 2408
Medical Treatment for Endometriosis: One Size Does Not Fit All
Endometriosis is associated with nociceptive pain, as well as peripheral and central sensitization. Evidence-based treatment suggestions for controlling endometriosis should be based on the convergence of the best scientific evidence, physicians’ clinical expertise, and the values and priorities of individual patients. In this non-systematic, comprehensive narrative review, data from available randomized controlled trials and meta-analyses on hormonal treatment for symptomatic endometriosis are interpreted through the lens of clinical experience. The role of patients in defining therapeutic trade-off balances is also taken into consideration. Most symptomatic patients benefit from hormonal therapy, including first-line (progestogens and estrogen-progestogen combinations) and second-line (GnRH agonists and antagonists) medications, to relieve nociceptive pain. To reduce the risk of venous and arterial thrombosis and avoid stimulating lesions, it is preferable to use combinations containing body-identical estrogens rather than ethinyl-estradiol. The main adverse effect of first-line medications is irregular bleeding, which adversely impacts efficacy, tolerability, and adherence. If progestogens and estrogen-progestogens do not improve health-related quality of life (HRQoL), promptly stepping up to GnRH analogues combined with add-back therapy is indicated. Add-on rather than upfront combination therapy is suggested. Separating the analogues and add-back therapy allows for choosing the compounds that best suit the characteristics of individual patients. Transdermal body-identical estradiol use is proposed in combination with both progestogens and GnRH analogues. Similar satisfactory outcomes are achieved with GnRH agonists and antagonists. Evidence on the use of neuromodulatory drugs to treat neuropathic and nociplastic pain is derived from studies of other chronic pain conditions and shows limited effectiveness. The two mainstays of hormonal therapy are (i) ovariostasis and (ii) amenorrhea. “Medical treatment failure” should not be declared unless a shift from first-line to second-line medications has been undertaken whenever these conditions are not met. For severely symptomatic adolescents and young women, secondary prevention through ovariostasis and amenorrhea should be pursued promptly to improve HRQoL, halt lesion progression, and preserve reproductive potential.
- 21 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (6) , 2408
Open AccessMedical Treatment for Endometriosis: One Size Does Not Fit All
Endometriosis is associated with nociceptive pain, as well as peripheral and central sensitization. Evidence-based treatment suggestions for controlling endometriosis should be based on the convergence of the best scientific evidence, physicians’ clinical expertise, and the values and priorities of individual patients. In this non-systematic, comprehensive narrative review, data from available randomized controlled trials and meta-analyses on hormonal treatment for symptomatic endometriosis are interpreted through the lens of clinical experience. The role of patients in defining therapeutic trade-off balances is also taken into consideration. Most symptomatic patients benefit from hormonal therapy, including first-line (progestogens and estrogen-progestogen combinations) and second-line (GnRH agonists and antagonists) medications, to relieve nociceptive pain. To reduce the risk of venous and arterial thrombosis and avoid stimulating lesions, it is preferable to use combinations containing body-identical estrogens rather than ethinyl-estradiol. The main adverse effect of first-line medications is irregular bleeding, which adversely impacts efficacy, tolerability, and adherence. If progestogens and estrogen-progestogens do not improve health-related quality of life (HRQoL), promptly stepping up to GnRH analogues combined with add-back therapy is indicated. Add-on rather than upfront combination therapy is suggested. Separating the analogues and add-back therapy allows for choosing the compounds that best suit the characteristics of individual patients. Transdermal body-identical estradiol use is proposed in combination with both progestogens and GnRH analogues. Similar satisfactory outcomes are achieved with GnRH agonists and antagonists. Evidence on the use of neuromodulatory drugs to treat neuropathic and nociplastic pain is derived from studies of other chronic pain conditions and shows limited effectiveness. The two mainstays of hormonal therapy are (i) ovariostasis and (ii) amenorrhea. “Medical treatment failure” should not be declared unless a shift from first-line to second-line medications has been undertaken whenever these conditions are not met. For severely symptomatic adolescents and young women, secondary prevention through ovariostasis and amenorrhea should be pursued promptly to improve HRQoL, halt lesion progression, and preserve reproductive potential.
- Open Access
- 4 February 2026
- Published by MDPI AG in Preprints.org
Medical Treatment for Endometriosis: One Size Does Not Fit All
Endometriosis is associated with nociceptive pain and with peripheral as well as central sensitization. To relieve nociceptive pain, most symptomatic patients benefits from hormonal therapy, which includes first-line (progestogens and estrogen-progestogen combinations) and second-line (GnRH agonists and antagonists) medications. To reduce venous and arterial thrombotic risk and avoid lesion stimulation, combinations containing bioidentical estrogens should be preferred to those containing ethinyl-estradiol. Irregular bleeding is the main adverse effect of first-line medications, adversely impacting efficacy, tolerability, and adherence. When progestogens and estrogen-progestogens do not improve the quality of life, prompt stepping up to GnRH analogues combined with add-back therapy is indicated. An add-on rather than upfront combination therapy is suggested. Keeping analogues and add-back therapy separate allows for the choice of the compounds that best suit individual patients’ characteristics. The transdermal use of bioidentical estradiol is suggested in combination with both progestogens and GnRH analogues. Similar satisfactory outcomes are achieved with GnRH agonists and antagonists. The evidence on neuromodulatory drugs to treat neuropathic and nociplastic pain is derived from other chronic pain conditions, and it demonstrates a limited effect. The two mainstays of hormonal therapy are i) ovariostasis and ii) amenorrhea. Whenever these are not obtained, and a shift from first-line to second-line medications has not been undertaken, “medical treatment failure” must not be declared. In severely symptomatic adolescents and young women, secondary prevention via ovariostasis and amenorrhea should be promptly pursued to improve quality of life, halt lesion progression, and preserve the reproductive potential.
- 4 February 2026
- Published by MDPI AG in Preprints.org
Open AccessMedical Treatment for Endometriosis: One Size Does Not Fit All
Endometriosis is associated with nociceptive pain and with peripheral as well as central sensitization. To relieve nociceptive pain, most symptomatic patients benefits from hormonal therapy, which includes first-line (progestogens and estrogen-progestogen combinations) and second-line (GnRH agonists and antagonists) medications. To reduce venous and arterial thrombotic risk and avoid lesion stimulation, combinations containing bioidentical estrogens should be preferred to those containing ethinyl-estradiol. Irregular bleeding is the main adverse effect of first-line medications, adversely impacting efficacy, tolerability, and adherence. When progestogens and estrogen-progestogens do not improve the quality of life, prompt stepping up to GnRH analogues combined with add-back therapy is indicated. An add-on rather than upfront combination therapy is suggested. Keeping analogues and add-back therapy separate allows for the choice of the compounds that best suit individual patients’ characteristics. The transdermal use of bioidentical estradiol is suggested in combination with both progestogens and GnRH analogues. Similar satisfactory outcomes are achieved with GnRH agonists and antagonists. The evidence on neuromodulatory drugs to treat neuropathic and nociplastic pain is derived from other chronic pain conditions, and it demonstrates a limited effect. The two mainstays of hormonal therapy are i) ovariostasis and ii) amenorrhea. Whenever these are not obtained, and a shift from first-line to second-line medications has not been undertaken, “medical treatment failure” must not be declared. In severely symptomatic adolescents and young women, secondary prevention via ovariostasis and amenorrhea should be promptly pursued to improve quality of life, halt lesion progression, and preserve the reproductive potential.
- Open Access
- 27 January 2026
- Published by Springer Nature
- Vol. 313 (1) , 62
Celebrating 30 years since the Gerhard Leyendecker and colleagues’ formulation of the hyper-dysperistalsis theory in endometriosis
- 27 January 2026
- Published by Springer Nature
- Vol. 313 (1) , 62
Open AccessCelebrating 30 years since the Gerhard Leyendecker and colleagues’ formulation of the hyper-dysperistalsis theory in endometriosis
- 8 November 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (2) , 102779
Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models
- 8 November 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (2) , 102779
Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models